HLN

Haleon
D

HLN

Arincen73/100B

Haleon financials

Yes. Haleon earned 1.62B GBP of net income over the last twelve months, 14.5% of its revenue. It made a profit in 7 of its 7 fiscal years since 2019.

Revenue (TTM)
11.16B GBP
Net income (TTM)
1.62B GBP
Free cash flow (TTM)
2.05B GBP
Cash and short-term investments
821.01M GBP
Total debt
8.20B GBP
Shareholders' equity
16.28B GBP

Cash, debt and equity as of 30 Jun 2026.

Haleon earnings

Next earnings · H2 FY2026
EPS estimate
0.28 USD
Revenue estimate
7.58B USD
Last quarter · H1 FY2026
EPS0.28Beat +3.6%Revenue7.52BBeat +17.5%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
H2 FY20260.28——+7.55%7.58B——+0.91%
H1 FY20260.270.28+3.63%+13.59%6.40B7.52B+17.50%+3.72%
H2 FY20250.250.26+3.38%+14.46%7.57B7.51B-0.79%+5.16%
H1 FY20250.240.24-0.57%+102.92%7.48B7.25B-3.03%+3.04%
H2 FY20240.220.23+5.24%—6.91B7.14B+3.31%—
H2 FY20240.110.23+109.36%—7.31B7.28B-0.29%—
H1 FY20240.110.12+9.09%-44.37%7.03B7.04B+0.05%-3.31%

Haleon growth and profitability

Full income statement
Revenue (TTM)
11.16B GBP
Net income (TTM)
1.62B GBP
Gross margin
65.54%
Operating margin
23.26%
Net margin
14.55%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY202511.03B-1.81%1.67B+15.60%63.35%21.87%15.11%2.88B+8.99%
FY202411.23B-0.61%1.44B+37.46%61.85%19.64%12.84%2.64B+12.38%
FY202311.30B+4.09%1.05B-1.04%61.59%17.66%9.28%2.35B+7.70%
FY202210.86B+13.76%1.06B-23.74%60.57%16.81%9.76%2.18B-1.27%
FY20219.55B-3.51%1.39B+21.40%62.34%17.16%14.56%2.21B+15.70%

How Haleon makes its money

Revenue11.03B 100.0%
Cost of revenue3.83B 34.7%
Gross profit6.99B 63.3%
Research and development308.10M 2.8%
Selling and administration4.36B 39.6%
Operating income2.41B 21.9%
Tax461.66M 4.2%
Other expense283.34M 2.6%
Net income1.67B 15.1%

FY2025, in GBP. Each band is as wide as its money; the percentage is its share of revenue.

Haleon revenue breakdown

By product

FY2025
Respiratory Health: 65.5%Digestive Health: 34.5%65.5%Respiratory Health34.5%Digestive Health
SegmentRevenueShare of revenueChange on the year
Respiratory Health1.87B65.5%+18.6%
Digestive Health987.00M34.5%—

By region

FY2022
Rest of World: 56.2%United States: 35.1%China: 8.6%56.2%Rest of World35.1%United States8.6%China
RegionRevenueShare of revenueChange on the year
Rest of World5.91B56.2%—
United States3.69B35.1%—
China907.00M8.6%—

Operating and free cash flow

Full cash flow statement
Operating cash flow Free cash flow
Fiscal yearOperating cash flowFree cash flow
FY20252.63B2.32B
FY20242.30B2.05B
FY20232.10B1.76B
FY20222.06B1.74B
FY20211.36B1.06B
FY20201.41B1.09B
FY2019786.00M543.00M

Haleon financial health

Full balance sheet
Cash and short-term investments
821.01M GBP
Total debt
8.20B GBP
Net cash
-7.38B GBP
Free cash flow (TTM)
2.05B GBP
Current ratio
0.69
Debt to equity
0.50
Piotroski score
8 / 9
Altman Z-score
2.87

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY20251.32B8.59B2.32B
FY20242.31B10.10B2.05B
FY20231.04B9.46B1.76B
FY2022684.00M10.44B1.74B
FY2021414.00M991.00M1.06B

Assets, liabilities and equity

Total assets Total liabilities Shareholders' equity
Fiscal yearTotal assetsTotal liabilitiesShareholders' equity
FY202532.57B16.12B16.40B
FY202434.32B18.09B16.17B
FY202334.06B17.33B16.61B
FY202234.82B18.36B16.33B
FY202134.45B7.97B26.36B
FY202034.13B7.91B26.11B
FY201935.71B8.30B27.32B

Haleon valuation

Price to earnings ratio (TTM)
19.30
Forward P/E (FY2026)
16.63
Price to sales (TTM)
2.73
Price to book
1.87
EV / EBITDA (TTM)
12.85

Capital structure

Market capitalization
40.29B USD
+
Total debt
10.84B USD
−
Cash and short-term investments
1.08B USD
=
Enterprise value
50.05B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)14.54————
FY2027 (est.)15.6214.54———
FY2026 (est.)16.6315.62———
Now (TTM)19.3015.742.731.8712.85
FY202520.8418.023.052.0514.20
FY202423.8220.603.102.1516.17
FY202326.9618.482.651.8016.33
FY202227.5618.732.811.8718.46
FY202118.47—2.680.9711.83

Haleon against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Zoetis, Viatris, Elanco Animal Health, Amneal Pharmaceuticals, and Lantheus Holdings, the US Drug Manufacturers - Specialty & Generic companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Below its median19.3
    17.548.9
  • Gross marginHighest in 5 years63.3%
    60.6%63.3%
    Against its peers: 2 of 6Peers' median 43.5%
  • Operating marginHighest in 5 years21.9%
    16.8%21.9%
    Against its peers: 2 of 6Peers' median 14.0%
  • Net marginHighest in 5 years15.1%
    9.3%15.1%
    Against its peers: 3 of 6Peers' median 2.4%
  • Return on equityHighest in 5 years10.2%
    5.3%10.2%
    Against its peers: 3 of 5Peers' median 8.9%
  • Free cash flow marginHighest in 5 years21.0%
    11.1%21.0%
    Against its peers: 3 of 6Peers' median 13.5%
  • Revenue growthBelow its median-1.8%
    -3.5%13.8%
    Against its peers: 5 of 6Peers' median 2.3%
  • EPS growthAt its median12.5%
    -20.0%33.3%
    Against its peers: 1 of 4Peers' median -21.8%
  • Debt to EBITDABelow its median2.98×
    0.45×4.78×
    Against its peers: 3 of 5Peers' median 3.43×
  • Current ratioLowest in 5 years0.92
    0.921.24
    Against its peers: 6 of 6Peers' median 2.17

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Haleon dividends

Annual dividend
0.13 USD
Dividend yield (indicated)
1.41%
Payout ratio
41.63%
Frequency
Semi-annual
Last payment
0.06 USD
Last ex-dividend date
14 Aug 2026
Last payment date
17 Sept 2026

Dividends per share

Year202520242023
Dividends per share0.180.160.10

Haleon ownership

Institutions
13.21%
Institutional holders
654 (+21)
Free float
99.87%

Who owns the shares

Institutions 13.2% Others 86.8%
As of 30 Jun 2026

Shares free to trade

Free float 4.38B shares ·99.9% Closely held 5.75M shares ·0.1%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY20254.48B4.51B-1.79%
FY20244.57B4.59B-0.95%
FY20234.63B4.63B+0.26%
FY20224.62B4.62B+0.05%
FY20214.62B4.62B0.00%

Common questions about Haleon's financials

Source: Financial Modeling Prep